Abstract
China faces a disproportionate cancer burden to the population size and is undergoing a transition in the cancer spectrum. We extracted data in five aspects of cancer incidence, mortality, survival, staging distributions, and attribution to risk factors in China, the USA and worldwide from open-source databases. We conducted a comprehensive secondary analysis of cancer profiles in China in the above aspects, and compared cancer statistics between China and the USA. A total of 4,546,400 new cancer cases and 2,992,600 deaths occurred in China in 2020, accounting for 25.1% and 30.2% of global cases, respectively. Lifestyle-related cancers including lung cancer, colorectal cancer, and breast cancer showed an upward trend and have been the leading cancer types in China. 41.6% of new cancer cases and 49.3% of cancer deaths occurred in digestive-system cancers in China, and the cancers of esophagus, nasopharynx, liver, and stomach in China accounted for over 40% of global cases. Infection-related cancers showed the highest population-attributable fractions among Chinese adults, and most cancers could be attributed to behavioral and metabolic factors. The proportions of stage I for most cancer types were much higher in the USA than in China, except for esophageal cancer (78.2% vs. 41.1%). The 5-year relative survival rates in China have improved substantially during 2000–2014, whereas survival for most cancer types in the USA was significantly higher than in China, except for upper gastrointestinal cancers. Our findings suggest that although substantial progress has been made in cancer control, especially in digestive system cancers in China, there was still a considerable disparity in cancer burden between China and the USA. More robust policies on risk factors and standardized screening practices are urgently warranted to curb the cancer growth and improve the prognosis for cancer patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C.J., Estève, J., et al. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075.
An, L., Zheng, R., Zeng, H., Zhang, S., Chen, R., Wang, S., Sun, K., Li, L., Wei, W., and He, J. (2023). The survival of esophageal cancer by subtype in China with comparison to the United States. Intl J Cancer 152, 151–161.
Bai, R., Sun, J., Xu, Y., Sun, Z., and Zhao, X. (2022). Incidence and mortality trends of nasopharynx cancer from 1990 to 2019 in China: an age-period-cohort analysis. BMC Public Health 22, 1351.
Brajcich, B.C., Yang, A.D., Keswani, R.N., Kreutzer, L., Molt, P.L., Rossi, M.B., Bilimoria, K.Y., and Halverson, A.L. (2022). The quality of screening colonoscopy in rural and underserved areas. Surg Endosc 36, 4845–4853.
Brawley, O.W. (2017). The role of government and regulation in cancer prevention. Lancet Oncol 18, e483–e493.
Bray, F., Jemal, A., Grey, N., Ferlay, J., and Forman, D. (2012). Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 13, 790–801.
Cai, Y., Chen, W., Wang, X., Xia, X., Cui, X., Wu, S., and Li, J. (2021). Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during 2008–2017. Chin J Cancer Res 33, 627–636.
Cao, M., Ding, C., Xia, C., Li, H., Sun, D., He, S., and Chen, W. (2021a). Attributable deaths of liver cancer in China. Chin J Cancer Res 33, 480–489.
Cao, M., Li, H., Sun, D., He, S., Yu, Y., Li, J., Chen, H., Shi, J., Ren, J., Li, N., et al. (2021b). Cancer screening in China: the current status, challenges, and suggestions. Cancer Lett 506, 120–127.
Cao, W., Chen, H.D., Yu, Y.W., Li, N., and Chen, W.Q. (2021c). Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 134, 783–791.
Chen, G., Sun, L., Gu, X., Ai, L., Yang, J., Zhang, Z., Hou, P., Wang, Y., Ou, X., Jiang, X., et al. (2023). FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway. Sci China Life Sci doi: https://doi.org/10.1007/s11427-023-2343-y.
Chen, W.Q., Li, N., Cao, M.M., Ren, J.S., Shi, J.F., Chen, H.D., Li, J., Lin, C.Q., Yu, X.Y., Cui, H., et al. (2020). Preliminary analysis of cancer screening program in urban China from 2013 to 2017 (in Chinese). China Cancer 29, 1–6.
Chen, W., Xia, C., Zheng, R., Zhou, M., Lin, C., Zeng, H., Zhang, S., Wang, L., Yang, Z., Sun, K., et al. (2019). Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health 7, e257–e269.
Chen, Z. (2008). The Third National Death Survey Report (in Chinese). Beijing: Peking Union Medical College Publication House. 11–12.
Cogliano, V.J., Baan, R., Straif, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Freeman, C., et al. (2011). Preventable exposures associated with human cancers. J Natl Cancer Inst 103, 1827–1839.
Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A., and Soerjomataram, I.F.B. (2020). Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from URL: https://gco.iarc.fr/today.
Force, L.M., Abdollahpour, I., Advani, S.M., Agius, D., Ahmadian, E., Alahdab, F., Alam, T., Alebel, A., Alipour, V., Allen, C.A., et al. (2019). The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol 20, 1211–1225.
Global Burden of Disease Collaborative Network. (2018). Global Burden of Disease Study 2017 (GDD 2017) results: Seattle, United States: Institute for Health Metrics and Evaluation (IHME). Available from URL: http://ghdx.healthdata.org/gbd-results-tool.
Gong, C., Cheng, Z., Yang, Y., Shen, J., Zhu, Y., Ling, L., Lin, W., Yu, Z., Li, Z., Tan, W., et al. (2022). A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Sci China Life Sci 65, 2205–2217.
He, S., Li, H., Cao, M., Sun, D., Yang, F., Yan, X., Zhang, S., Xia, C., Yu, Y., Zhao, L., et al. (2023). Geographic, demographic, and socioeconomic disparities and factors associated with cancer literacy in China: national cross-sectional study. JMIR Public Health Surveill 9, e43541.
Hooi, J.K.Y., Lai, W.Y., Ng, W.K., Suen, M.M.Y., Underwood, F.E., Tanyingoh, D., Malfertheiner, P., Graham, D.Y., Wong, V.W.S., Wu, J.C.Y., et al. (2017). Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153, 420–429.
Islami, F., Goding Sauer, A., Miller, K.D., Siegel, R.L., Fedewa, S.A., Jacobs, E.J., McCullough, M.L., Patel, A.V., Ma, J., Soerjomataram, I., et al. (2018). Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 68, 31–54.
Jeng, W.J., Papatheodoridis, G.V., and Lok, A.S.F. (2023). Hepatitis B. Lancet 401, 1039–1052.
Jia, S., Li, H., Zeng, H., Zheng, R., Li, J., Shi, J., Yang, Z., Cao, M., and Chen, W. (2019). Association of cancer prevention awareness with esophageal cancer screening participation rates: results from a population-based esophageal cancer screening program in rural China. Chin J Cancer Res 31, 601–608.
Jiang, H., Room, R., and Hao, W. (2015). Alcohol and related health issues in China: action needed. Lancet Glob Health 3, e190–e191.
Ju, W., Zheng, R., Zhang, S., Zeng, H., Sun, K., Wang, S., Chen, R., Li, L., Wei, W., and He, J. (2023). Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea. Sci China Life Sci 66, 1079–1091.
Li, J., Li, H., Zeng, H., Zheng, R., Cao, M., Sun, D., He, S., Ren, J., Chen, W., and He, J. (2021). Trends in high-risk rates and screening rates for the population-based cancer screening program on esophageal, stomach and liver cancer in China, 2010–2016. J Natl Cancer Center 1, 101–107.
Li, M., Sun, Y., Yang, J., Martel, C., Charvat, H., Clifford, G.M., Vaccarella, S., and Wang, L. (2020). Time trends and other sources of variation in Helicobacter pylori infection in mainland China: a systematic review and meta-analysis. Helicobacter 25, e12729.
Li, Y., Wang, D.D., Ley, S.H., Vasanti, M., Howard, A.G., He, Y., and Hu, F.B. (2017). Time trends of dietary and lifestyle factors and their potential impact on diabetes burden in China. Diabetes Care 40, 1685–1694.
Mao, W., Tang, S., Zhu, Y., Xie, Z., and Chen, W. (2017). Financial burden of healthcare for cancer patients with social medical insurance: a multi-centered study in urban China. Int J Equity Health 16, 180.
Mi, Y.J., Zhang, B., Wang, H.J., Yan, J., Han, W., Zhao, J., Liu, D.W., and Tian, Q.B. (2015). Prevalence and secular trends in obesity among Chinese adults, 1991–2011. Am J Prev Med 49, 661–669.
National Health Commission. (2019). Healthy China Action: Cancer Prevention and Control Implementation Plan (2019–2022). Beijing: National Health Commission. April 10, 2023. Available from URL: http://www.nhc.gov.cn/jkj/s5878/201909/2cb5dfb5d4f84f8881897e232 b376b60.shtml.
National Health Commission. (2023). China Health Statistical Yearbook 2022. Beijing: National Health Commission. April 11, 2023. Available from URL: http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1e-b9375e01a0faa1fb.shtml.
Roberts, H., Ly, K.N., Yin, S., Hughes, E., Teshale, E., and Jiles, R. (2021). Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US Households, 2013–2018. Hepatology 74, 2353–2365.
Sarma, E.A., Rendle, K.A., and Kobrin, S.C. (2020). Cancer symptom awareness in the US: sociodemographic differences in a population-based survey of adults. Prev Med 132, 106005.
SEER. (2019). SEER*Stat Databases: November 2019 Submission. Available from URL: https://seer.cancer.gov/data-software/documentation/seerstat/nov2019/.
Shan, T., Ran, X., Li, H., Feng, G., Zhang, S., Zhang, X., Zhang, L., Lu, L., An, L., Fu, R., et al. (2023). Disparities in stage at diagnosis for liver cancer in China. J Natl Cancer Center 3, 7–13.
Shi, J., Cao, M., Wang, Y., Bai, F., Lei, L., Peng, J., Feletto, E., Canfell, K., Qu, C., and Chen, W. (2021). Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer 148, 1051–1065.
Su, B., Zhong, P., Xuan, Y., Xie, J., Wu, Y., Chen, C., Zhao, Y., Shen, X., and Zheng, X. (2023). Changing patterns in cancer mortality from 1987 to 2020 in China. Cancers 15, 476.
Sun, D., Li, H., Cao, M., He, S., Lei, L., Peng, J., and Chen, W. (2020). Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med 17, 879–895.
Sun, Z., Chen, T., Thorgeirsson, S.S., Zhan, Q., Chen, J., Park, J.H., Lu, P., Hsia, C.C., Wang, N., Xu, L., et al. (2013). Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 34, 1800–1805.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209–249.
Tanaka, M., Katayama, F., Kato, H., Tanaka, H., Wang, J., Qiao, Y.L., and Inoue, M. (2011). Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 21, 401–416.
Ugai, T., Sasamoto, N., Lee, H.Y., Ando, M., Song, M., Tamimi, R.M., Kawachi, I., Campbell, P.T., Giovannucci, E.L., Weiderpass, E., et al. (2022). Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol 19, 656–673.
United Nations, Department of Economic and Social Affairs, Population Division. (2022). World Population Prospects 2022: Summary of Results. UN DESA/POP/2022/TR/NO. 3. Available from URL: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf.
Wang, H., Men, P., Xiao, Y., Gao, P., Lv, M., Yuan, Q., Chen, W., Bai, S., and Wu, J. (2019). Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis 19, 811.
Wang, L., Gao, P., Zhang, M., Huang, Z., Zhang, D., Deng, Q., Li, Y., Zhao, Z., Qin, X., Jin, D., et al. (2017). Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317, 2515–2523.
Wang, Y., Yan, Q., Fan, C., Mo, Y., Wang, Y., Li, X., Liao, Q., Guo, C., Li, G., Zeng, Z., et al. (2023). Overview and countermeasures of cancer burden in China. Sci China Life Sci doi: https://doi.org/10.1007/s11427-022-2240-6.
Wei, W., Zeng, H., Zheng, R., Zhang, S., An, L., Chen, R., Wang, S., Sun, K., Matsuda, T., Bray, F., et al. (2020). Cancer registration in China and its role in cancer prevention and control. Lancet Oncol 21, e342–e349.
World Cancer Research Fund/American Institute for Cancer Research. (2018). Diet, nutrition, physical activity and cancer: a global perspective (the Third Expert Report). Continuous Update Project Expert Report 2018.
World Health Organization. (2018). Global adult tobacco survey (GATS) Fact sheet China. Available from URL: https://www.who.int/docs/default-source/wpro-documents/countries/China/2018-gats-China-factsheet-cn-en.pdf?sfvrsn=3f4e2-da9_2.
Wu, C., Li, M., Meng, H., Liu, Y., Niu, W., Zhou, Y., Zhao, R., Duan, Y., Zeng, Z., Li, X., et al. (2019). Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci 62, 640–647.
Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., Yang, F., Yan, X., Zhang, S., Li, N., et al. (2022). Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 135, 584–590.
Xin, L., Gao, Y., Cheng, Z., Wang, T., Lin, H., Pang, Y., Sun, C., Fu, Z., Li, Z., Ma, X., et al. (2022). Utilization and quality assessment of digestive endoscopy in China: results from 5-year consecutive nationwide surveys. Chin Med J 135, 2003–2010.
Zang, J., and Ng, S.W. (2016). Age, period and cohort effects on adult physical activity levels from 1991 to 2011 in China. Int J Behav Nutr Phys Act 13, 40.
Zeng, H., Chen, W., Zheng, R., Zhang, S., Ji, J.S., Zou, X., Xia, C., Sun, K., Yang, Z., Li, H., et al. (2018). Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 6, e555–e567.
Zeng, H., Ran, X., An, L., Zheng, R., Zhang, S., Ji, J.S., Zhang, Y., Chen, W., Wei, W., and He, J. (2021). Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health 6, e877–e887.
Zhang, R., He, Y., Wei, B., Lu, Y., Zhang, J., Zhang, N., He, R., Xue, H., and Zhu, B. (2023). Nasopharyngeal carcinoma burden and its attributable risk factors in china: estimates and forecasts from 1990 to 2050. Int J Environ Res Public Health 20, 2926.
Zhao, T., Cheng, J., Chai, J., Feng, R., Liang, H., Shen, X., Sha, R., and Wang, D. (2016). Inpatient care burden due to cancers in Anhui, China: a cross-sectional household survey. BMC Public Health 16, 308.
Zhou, X.Z., Lyu, N.H., Zhu, H.Y., Cai, Q.C., Kong, X.Y., Xie, P., Zhou, L.Y., Ding, S.Z., Li, Z.S., and Du, Y.Q. (2023). Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention. Gut 72, 855–869.
Zou, Q., Wang, H., Du, W., Su, C., Ouyang, Y., Wang, Z., Ding, G., and Zhang, B. (2020). Trends in leisure-time physical activity among Chinese adults—China, 2000–2015. China CDC Weekly 2, 135–139.
Acknowledgement
This work was supported by the National Natural Science Foundation of China (82273721), the Jing-jin-ji Special Projects for Basic Research Cooperation (J200017) and the Sanming Project of the Medicine in Shenzhen (SZSM201911015). The views expressed are those of the authors only and do not represent any official position of the National Cancer Center (NCC) of China, Cancer Hospital, Chinese Academy of Medical Sciences (CHCAMS), Chinese Academy of Medical Sciences (CAMS), or Peking Union Medical College (PUMC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The author(s) declare that they have no conflict of interest.
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
He, S., Xia, C., Li, H. et al. Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors. Sci. China Life Sci. 67, 122–131 (2024). https://doi.org/10.1007/s11427-023-2423-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-023-2423-1